4:10 pm Achillion Pharma advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, into clinical trial; initiates Phase 2 pilot study with ACH-3102, NS5A Inhibitor, for HCV
View todays social media effects on ACHN
View the latest stocks trending across Twitter. Click to view dashboard
See who Achillion is hiring next, click here to view
